CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed
Drug / intervention
Beta-blockers including Carvedilol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00344513
NCT00344513Phase 4Completed
CompareCT.gov

Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF): An Internet-based Registry and Process of Care Improvement Program for Heart Failure Patients

GlaxoSmithKline·interventional·Posted Jun 26, 2006·Updated Nov 24, 2020

In Brief

A Phase 4 clinical trial evaluating Beta-blockers including Carvedilol and ACE inhibitors for Heart Failure, Congestive. Completed.

Detailed Summary

This program is designed to improve medical care and education of hospitalized patients with heart failure and accelerate the initiation of evidence-based heart failure guideline recommended therapies by administering them before hospital discharge. A registry component focusing on admission to discharge and 60- to 90-day follow-up is designed to evaluate the demographic, pathophysiologic, clinical, treatment, and outcome characteristics of patients hospitalized with heart failure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure, Congestive
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 26, 2006
Enrollment StartDec 16, 2002
Study CompletionJun 30, 2005
TodayJul 2, 2026
Posted 20.0 years ago

Interventions

Beta-blockers including Carvediloldrug

ACE inhibitorsdrug